Eisai DELPHIA Dementia with Lewy Bodies

Currently Enrolling!

The Delphia study will test an investigational medication to see if it might improve cognitive function, including attention, memory, and language in patients who have dementia with Lewy bodies (DLB).

Key Inclusion:

Patients may qualify for this study if they: 

  • Are age 50-85 
  • Have probable DLB 
  • Have no neurological condition contributing to cognitive impairment beyond those caused by DLB 
  • Patients enrolled in this study must have a caregiver, friend, or family member who can provide information about the patient throughout the study. This person will attend all study visits with the subject. 

Axsome Therapeutics, inc. ADVANCE

Currently Enrolling!

Many individuals with Alzheimer’s Dementia may experience agitation in addition to memory and cognitive difficulties. If you or someone you know is struggling with symptoms of agitation, the ADVANCE study may be a good option for you. The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational product for symptoms of agitation in those with Alzheimer’s.

Individuals that meet requirements: 

  • Are male or female, 65-90 years old
  • Have a diagnosis of probable Alzheimer’s Dementia alongside symptoms of agitation
  • Must have an available caregiver 
  • Currently take medication for Alzheimer’s (e.g., Donepezil, Memantine)

Suvn Life Sciences Ltd.

Currently Enrolling!

This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects from 50-85 years of age with moderate Alzheimer’s disease receiving stable doses of donepezil HCl and memantine HCl.

Individuals that meet requirements:

  • Are Male or Female between 50-85 years old
  • Are on the above-mentioned treatment(s) for 3 months prior to entering the study
  • Must have an available caregiver

Axsome Therapeutics, Inc

Currently Enrolling Participants!

Individuals with Major Depressive Disorder (MDD) may have failed one or more anti-depressant in the past. Axsome is investigating the efficacy of a product in those who have treatment resistant MDD (STRIDE study). If you suffer from Major Depression and have not found success in one or more anti-depressant medications, you may qualify for AXSOME’S STRIDE study!

Individuals that meet requirements:

  • Are male or Female between 18-65
  • Have a diagnosis of MDD
  • Have taken 1 or 2 anti-depressants for their current MDD episode, one of which is not Wellbutrin (Bupropion).  

CHICKADEE Adolescent Females (under 18)

Currently Enrolling!

The Chickadee Study is a research study in teens with postpartum depression (PPD). You may qualify if you are 15 to 17 years old and have had a baby in the last six months.

Individuals that meet requirements:

  • Adolescent females 17 years of age or younger
  • Have given birth within the last 6 months
  • Frequently feel extremely sad, anxious, or overwhelmed, and these symptoms are associated with PPD
  • Have symptoms that began no earlier than the third trimester and no later than the first four weeks following delivery
  • Be willing to temporarily cease breastfeeding for 7 days
 

No Longer Enrolling

Teens and Young Adults Depression Study

This study examined the safety and efficacy for a non-drug therapy (i.e., NeuroStar TMS therapy) for teens or young adults suffering from depression. Study participants received the non-invasive, TMS treatment for no-cost. This non-drug treatment has been FDA-cleared for adults (22-70 years old). If you are interested in reading about the results of this study, or wish to know more information about NeuroStar TMS therapy for the treatment of depression, please click the link(s) below.

Hummingbird Postpartum Depression Trial

The Hummingbird study evaluated an investigational medication in women with moderate to severe postpartum depression. Postpartum depression is a biological complication of pregnancy, including symptoms of sadness, anger, loss of pleasure, and cognitive, emotional, physical symptoms.  Over 100 women participated in the Hummingbird study across 22 states in the U.S. and over 40 different study sites. More information about the trial can be found below from the following link(s).

Sprites Study

The SPRITES study examined how sertraline or psychotherapy affects aspects of cognitive, emotional, and physical development in children who are diagnosed with an anxiety, depressive, or obsessive-compulsive disorder.  In addition, the study examined the long-term effects that sertraline may or may not have on children and adolescent development. If you would like to learn more about this study, please click the link(s) below. 

Evaluating Gait and Balance in Subjects with Dementia

Several researchers have found that individuals diagnosed with dementia have a higher likelihood of experiencing episodes of falling or issues with balance. This study examined the effects of intepirdine (RVT-101) on gait and balance in individuals with Alzheimer’s Disease, Lewy Body Dementia, or Parkinson’s Dementia. More information about this study and its results can be found below by clicking on the following link(s). 

Study_2.png

Mindset Study

MINDSET is phase II clinical research program that evaluated the investigational medication, RVT-101, for the treatment of mild-to-moderate Alzheimer’s Disease. Researchers investigated the efficacy of combining RVT-101 with Donepezil in cognitive abilities and performance on activities of daily living. This worldwide research trial enrolled over 1,000 participants across hundreds of research sites. More information on the MINDSET study can be found by clicking the link(s) below. 

Study_3.png

PrecisionMed Trial

Not Currently Enrolling

This study involved administering several cognitive tests on individuals 50 years and older who have a diagnosis of Mild Alzheimer’s Disease or Mild Cognitive Impairment.

Reverse-SD

Not Currently Enrolling

Those who have symptoms of cognitive declines, such as issues with thinking, judgment, or memory, may be experiencing Mild Cognitive Impairment (MCI) or have already been diagnosed with MCI. This clinical trial is evaluating an investigational drug for those who are experiencing MCI, or mild Alzheimer’s Dementia.

Individuals that meet requirements:

  • Are male or female between the ages of 55-85 years old
  • Experience symptoms of MCI, Mild AD, or have been diagnosed with MCI (more information available upon pre-screening)
  • Must have an available caregiver 
Results from Phase 2a clinical studies in patients with Early-Stage Alzheimer’s disease have been completed.

Sage Therapeutics Robin Study - Females 18 - 45

Not Currently Enrolling

This research study is evaluating the efficacy and safety of an investigational oral medication in adult women from 18 to 45 with Postpartum Depression. An investigational medication is a study drug that will be tested during a study to see if it is safe and effective for a specific condition and/or group of people.

To be eligible for the study, you must:

  • Be 18 to 45 years of age
  • Have given birth within the last 6 months
  • Frequently feel extremely sad, anxious, or overwhelmed, and these symptoms are associated with PPD
  • Have symptoms that began no earlier than the third trimester and no later than the first four weeks following delivery
  • Be willing to temporarily cease breastfreeding

The study doctor will discuss additional requirements.

Your participation in the Robin Study is completely voluntary. If you decide to participate in this research study, you are always free to withdraw at any time for any reason without any penalty or effect on your future medical care.

If you qualify and decide to participate:

  • You will receive study-related medical care and the assigned study drug provided at no cost
  • Transportation may be provided for those who require assistance 

Find Out More

Please call or email Anchor Neuroscience research staff if you are interested in learning more about studies for which you may quality or to be placed on our list of potential study subjects.